1,186
Views
0
CrossRef citations to date
0
Altmetric
Editorial

How long will my TAVI valve last, doctor?

&

References

  • Nathaniel S, Saligram S, Innasimuthu AL. Aortic stenosis: An update. World J Cardiol. 2010;2(6):135–139. doi: 10.4330/wjc.v2.i6.135
  • Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol. 1997;29(3):630–634. doi: 10.1016/S0735-1097(96)00563-3
  • Gahl B, Çelik M, Head SJ, et al. Natural history of asymptomatic severe aortic stenosis and the Association of early Intervention with outcomes: a systematic review and meta-analysis. JAMA Cardiol. 2020;5:1102–1112. doi: 10.1001/jamacardio.2020.2497
  • Kaneko T, Cohn LH, Aranki SF. Tissue valve is the preferred option for patients aged 60 and older. Circulation. 2013;128(12):1365–1371. doi: 10.1161/CIRCULATIONAHA.113.002584
  • Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106(24):3006–3008. doi: 10.1161/01.CIR.0000047200.36165.B8
  • Otto CM, Nishimura RA, Bonow RO, et al. ACC/AHA guideline for the management of patients with valvular Heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2020;143:e72–e227. (2021).
  • Vahanian A, Beyersdorf F, Praz F, et al. ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2021;43(7):561–632. (2022). doi: 10.1093/eurheartj/ehab395
  • Capodanno D, Petronio AS, Prendergast B, et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interve. Eur J Cardio-Thoracic Surg Off J Eur Assoc Cardio-Thoracic Surg. 2017;52(3):408–417. doi: 10.1093/ejcts/ezx244
  • Généreux P, Piazza N, Alu MC, et al. Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. J Am Coll Cardiol. 2021;77:2717–2746. doi: 10.1016/j.jacc.2021.02.038
  • Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016;374(17):1609–1620. doi: 10.1056/NEJMoa1514616
  • Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019;380(18):1695–1705. doi: 10.1056/NEJMoa1814052
  • Mack MJ, Leon M, Smith B, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet (London, England). 2015;385(9986):2477–2484. doi: 10.1016/S0140-6736(15)60308-7
  • Gleason TG, Reardon MJ, Popma JJ, et al. 5-year outcomes of self-expanding transcatheter versus surgical aortic valve replacement in high-risk patients. J Am Coll Cardiol. 2018;72(22):2687–2696. doi: 10.1016/j.jacc.2018.08.2146
  • CRT. Washington D5-year incidence of bioprosthetic valve dysfunction in patients randomized to surgery or TAVI: insights from the CoreValve US pivotal and SURTAVI trials. Washington DC. CRT Online; 2023.
  • Jørgensen TH, Thyregod HGH, Ihlemann N, et al. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement. Eur Heart J. 2021;42(30):2912–2919. doi: 10.1093/eurheartj/ehab375
  • Douglas PS, Leon MB, Mack MJ, et al. Longitudinal hemodynamics of transcatheter and surgical aortic valves in the PARTNER trial. JAMA Cardiol. 2017;2(11):1197–1206. doi: 10.1001/jamacardio.2017.3306
  • Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017;376(14):1321–1331. doi: 10.1056/NEJMoa1700456
  • Didier R, Eltchaninoff H, Donzeau-Gouge P, et al. Five-year clinical outcome and valve durability after transcatheter aortic valve replacement in high-risk patients. Circulation. 2018;138(23):2597–2607. doi: 10.1161/CIRCULATIONAHA.118.036866
  • Makkar RR, Blanke P, Leipsic J, et al. Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 cardiac computed tomography substudy. J Am Coll Cardiol. 2020;75(24):3003–3015. doi: 10.1016/j.jacc.2020.04.043
  • Blanke P, Leipsic JA, Popma JJ, et al. Bioprosthetic aortic valve leaflet thickening in the Evolut low risk Sub-Study. J Am Coll Cardiol. 2020;75(19):2430–2442. doi: 10.1016/j.jacc.2020.03.022
  • Ali N, Hildick-Smith D, Parker J, et al. Long-term durability of self-expanding and balloon-expandable transcatheter aortic valve prostheses: UK TAVI registry. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2023;101(5):932–942. doi: 10.1002/ccd.30627
  • Sathananthan J, Lauck S, Polderman J, et al. Ten Year follow-up of high-risk patients treated during the early experience with transcatheter aortic valve replacement. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2021;97(3):E431–E437. doi: 10.1002/ccd.29124
  • Barbanti M, Costa G, Zappulla P, et al. Incidence of Long-Term Structural Valve Dysfunction and Bioprosthetic Valve Failure After Transcatheter Aortic Valve Replacement. J Am Heart Assoc. 2018;7(15):e008440. doi: 10.1161/JAHA.117.008440
  • Eltchaninoff H, Durand E, Avinée G, et al. Assessment of structural valve deterioration of transcatheter aortic bioprosthetic balloon-expandable valves using the new European consensus definition. EuroIntervention J Eur Collab With Work Gr Interv Cardiol Eur Soc Cardiol. 2018;14(3):e264–e271. doi: 10.4244/EIJ-D-18-00015
  • Testa L, Latib A, Brambilla N, et al. Long-term clinical outcome and performance of transcatheter aortic valve replacement with a self-expandable bioprosthesis. Eur Heart J. 2020;41(20):1876–1886. doi: 10.1093/eurheartj/ehz925
  • Persson M, Glaser N, Nilsson J, et al. Comparison of long-term performance of bioprosthetic aortic valves in Sweden from 2003 to 2018. JAMA Netw Open. 2022;5(3):e220962. doi: 10.1001/jamanetworkopen.2022.0962
  • Bourguignon T, Bouquiaux-Stablo A-L, Candolfi P, et al. Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. Ann Thorac Surg. 2015;99(3):831–837. doi: 10.1016/j.athoracsur.2014.09.030
  • Fukuhara S, Brescia AA, Deeb GM. Surgical explantation of transcatheter aortic bioprostheses: an analysis from the Society of Thoracic surgeons database. Circulation. 2020;142(23):2285–2287. doi: 10.1161/CIRCULATIONAHA.120.050499
  • Landes U, Webb JG, De Backer O, et al. Repeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunction. J Am Coll Cardiol. 2020;75(16):1882–1893. doi: 10.1016/j.jacc.2020.02.051
  • Halim J, Brouwer J, Lycke M, et al. Transcatheter aortic valve replacement: impact of pre-procedural FEops HEARTguide assessment on device size selection in borderline annulus size cases. Neth Heart J. 2021;29(12):654–661. doi: 10.1007/s12471-021-01620-4

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.